Sarepta Therapeutics Inc (SRPT)
110.50
-0.36
(-0.32%)
USD |
NASDAQ |
Nov 21, 16:00
112.00
+1.50
(+1.36%)
Pre-Market: 08:01
Sarepta Therapeutics Enterprise Value: 10.58B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 10.58B |
| November 20, 2024 | 10.62B |
| November 19, 2024 | 10.21B |
| November 18, 2024 | 10.03B |
| November 15, 2024 | 10.01B |
| November 14, 2024 | 10.45B |
| November 13, 2024 | 10.77B |
| November 12, 2024 | 10.95B |
| November 11, 2024 | 11.29B |
| November 08, 2024 | 11.65B |
| November 07, 2024 | 11.53B |
| November 06, 2024 | 12.25B |
| November 05, 2024 | 11.97B |
| November 04, 2024 | 11.78B |
| November 01, 2024 | 11.81B |
| October 31, 2024 | 12.06B |
| October 30, 2024 | 12.23B |
| October 29, 2024 | 12.46B |
| October 28, 2024 | 12.47B |
| October 25, 2024 | 12.55B |
| October 24, 2024 | 12.64B |
| October 23, 2024 | 12.43B |
| October 22, 2024 | 12.29B |
| October 21, 2024 | 12.19B |
| October 18, 2024 | 12.16B |
| Date | Value |
|---|---|
| October 17, 2024 | 11.89B |
| October 16, 2024 | 12.05B |
| October 15, 2024 | 11.84B |
| October 14, 2024 | 11.91B |
| October 11, 2024 | 11.92B |
| October 10, 2024 | 11.72B |
| October 09, 2024 | 11.30B |
| October 08, 2024 | 11.46B |
| October 07, 2024 | 11.28B |
| October 04, 2024 | 11.53B |
| October 03, 2024 | 11.37B |
| October 02, 2024 | 11.73B |
| October 01, 2024 | 11.71B |
| September 30, 2024 | 11.96B |
| September 27, 2024 | 11.64B |
| September 26, 2024 | 11.67B |
| September 25, 2024 | 11.65B |
| September 24, 2024 | 11.73B |
| September 23, 2024 | 11.67B |
| September 20, 2024 | 11.90B |
| September 19, 2024 | 11.89B |
| September 18, 2024 | 11.69B |
| September 17, 2024 | 11.75B |
| September 16, 2024 | 11.62B |
| September 13, 2024 | 11.65B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.483B
Minimum
Jan 19 2022
15.34B
Maximum
Jun 24 2024
8.944B
Average
9.277B
Median
Oct 27 2022
Enterprise Value Benchmarks
| Catalyst Pharmaceuticals Inc | 2.077B |
| Madrigal Pharmaceuticals Inc | 6.299B |
| Vertex Pharmaceuticals Inc | 109.46B |
| Viking Therapeutics Inc | 4.823B |
| Regenxbio Inc | 199.36M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 33.61M |
| Revenue (Quarterly) | 467.17M |
| Total Expenses (Quarterly) | 444.98M |
| EPS Diluted (Quarterly) | 0.34 |
| Gross Profit Margin (Quarterly) | 80.37% |
| Profit Margin (Quarterly) | 7.19% |
| Earnings Yield | 1.39% |
| Operating Earnings Yield | 0.73% |
| Normalized Earnings Yield | 1.476 |